Feasibility of breast MRI after sentinel procedure for breast cancer with superparamagnetic tracers

Publication date: January 2018
Source:European Journal of Surgical Oncology, Volume 44, Issue 1
Author(s): Benedict Krischer, Serafino Forte, Tilo Niemann, Rahel A. Kubik-Huch, Cornelia Leo
RationaleThe gold standard for detection of axillary sentinel lymph nodes uses injection of a radioisotope (99Tc Nanocoll). As an alternative to this method, a magnetometer detecting the superparamagnetic tracer Sienna+^® can be applied for detection of sentinel lymph nodes.The goal of this study was to determine whether interpretation of breast MRI is impaired by Sienna+^® tracer residues in the operated breast and axillary lymph nodes after a sentinel procedure using this tracer.Patients and methods34 patients who received the Sienna+^® tracer for marking the sentinel node were invited to undergo a follow-up breast MRI. Native MR images were obtained from breast and axilla. The breast MRIs were evaluated by two independent breast radiologists for Sienna+^® tracer related artefacts and for the degree of impairment of the MR imaging.Results24 of the 34 invited patients took part in this study. The mean time since injection of Sienna+^® was 42 months (40.6–45.4 months). Two patients had bilateral surgery with injections in both breasts, leading to a total of 26 separate cases. One case had to be excluded due to breathing artefacts. In 10 cases (40%), impaired imaging was found. In three cases (12%), the MRI scan reading was impossible due to Sienna+^® tracer residues, the other 12 cases (48%) showed no restriction.In the subgroup of patients treated with breast conserving surgery, tracer residue artefacts were found in 13 of 17 patients (76.5%).ConclusionTo our knowledge, in this study for the first time MR feasibility after Sienna injection was investigated. Sienna+^® impaired breast MRI after a mean follow-up time of 42 months in half of the cases. Further research is needed to investigate time and field-strength dependency of tracer detectability as well as the diagnostic impact of these artifacts on contrast-enhanced imaging in a clinical setting.



http://ift.tt/2BBoT0I